Advertisement

Management of Psychiatric Medications During Perianesthesia Period

  • Paula Trigo-Blanco
  • Adriana Dana OpreaEmail author
Chapter

Abstract

Due to high prevalence of psychiatric disorders in the general population, the preoperative anesthesia plan often must address the risks of continuing or discontinuing the psychotropic medications prior to surgery. This chapter reviews the most important classes of psychotropic medications and their potential impact upon the clinical presentation pre- and postsurgery, as well as the most significant interactions between psychotropic medications and anesthesia agents.

Keywords

Anesthesia Preoperative evaluation Psychopharmacology Drug-to-drug interactions 

References

  1. 1.
    Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl R, Kessler RC, Demler O, et al. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull. World Health Organ. 2000;78(4):413–26.Google Scholar
  2. 2.
    Huyse FJ, Touw DJ, van Schijndel RS, de Lange JJ, Slaets JP. Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery. Psychosomatics. 2006;47(1):8–22.CrossRefGoogle Scholar
  3. 3.
    Strauss J. Psychotropic medication use in older adults. Int Anesthesiol Clin. 2014;52(4):77–94.CrossRefGoogle Scholar
  4. 4.
    Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533–40.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. J Clin Anesth. 2012;24(3):251–2.CrossRefGoogle Scholar
  6. 6.
    Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003;4(1):63–74.CrossRefGoogle Scholar
  7. 7.
    Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33(2):181–7.PubMedGoogle Scholar
  8. 8.
    Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81(9):1139–42.PubMedGoogle Scholar
  9. 9.
    Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331(15):1021–2.CrossRefGoogle Scholar
  10. 10.
    Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–9.CrossRefGoogle Scholar
  11. 11.
    Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615–9.CrossRefGoogle Scholar
  12. 12.
    Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010;48(7):9–12.CrossRefGoogle Scholar
  13. 13.
    Sajan F, Conte JV, Tamargo RJ, Riley LH, Rock P, Faraday N. Association of Selective Serotonin Reuptake Inhibitors with transfusion in surgical patients. Anesth Analg. 2016;123(1):21–8.CrossRefGoogle Scholar
  14. 14.
    Singh I, Achuthan S, Chakrabarti A, Rajagopalan S, Srinivasan A, Hota D. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf. 2015;24(3):237–45.CrossRefGoogle Scholar
  15. 15.
    Ama T, Bounmythavong S, Blaze J, Weismann M, Marienau MS, Nicholson WT. Implications of pharmacogenomics for anesthesia providers. AANA J. 2010;78(5):393–9.PubMedGoogle Scholar
  16. 16.
    Rizvi SM, Shaikh S, Khan M, Biswas D, Hameed N, Shakil S. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. CNS Neurol Disord Drug Targets. 2014;13(8):1427–31.CrossRefGoogle Scholar
  17. 17.
    Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med. 1982;306(16):954–9.CrossRefGoogle Scholar
  18. 18.
    Kroenke K, Gooby-Toedt D, Jackson JL. Chronic medications in the perioperative period. South Med J. 1998;91(4):358–64.CrossRefGoogle Scholar
  19. 19.
    Attri JP, Bala N, Chatrath V. Psychiatric patient and anaesthesia. Indian J Anaesth. 2012;56(1):8–13.CrossRefGoogle Scholar
  20. 20.
    el-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg. 1985;64(6):592–6.CrossRefGoogle Scholar
  21. 21.
    Ebrahim ZY, O’Hara J, Borden L, Tetzlaff J. Monoamine oxidase inhibitors and elective surgery. Cleve Clin J Med. 1993;60(2):129–30.CrossRefGoogle Scholar
  22. 22.
    Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. Pharmacotherapy. 2015;35(1):112–7.CrossRefGoogle Scholar
  23. 23.
    Noble WH, Baker A. MAO inhibitors and coronary artery surgery: a patient death. Can J Anaesth. 1992;39(10):1061–6.CrossRefGoogle Scholar
  24. 24.
    Takechi K, Abe T, Yorozuya T, Watanabe T, Nagaro T. Refractory hypotension during general anaesthesia caused by the long-term use of amoxapine. Anaesth Intensive Care. 2010;38(5):965–6.PubMedGoogle Scholar
  25. 25.
    Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John’s wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211–21.CrossRefGoogle Scholar
  26. 26.
    Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, et al. Extracorporeal treatment for Lithium poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin J Am Soc Nephrol. 2015;10(5):875–87.CrossRefGoogle Scholar
  27. 27.
    Hill GE, Wong KC, Hodges MR. Lithium carbonate and neuromuscular blocking agents. Anesthesiology. 1977;46(2):122–6.CrossRefGoogle Scholar
  28. 28.
    Leone CW. Anesthetic management of lithium-treated patients. Anesth Prog. 1984;31(3):138–40.PubMedPubMedCentralGoogle Scholar
  29. 29.
    LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291(5):605–14.CrossRefGoogle Scholar
  30. 30.
    Richelson E, El-Fakahany E. Changes in the sensitivity of receptors for neurotransmitters and the actions of some psychotherapeutic drugs. Mayo Clin Proc. 1982;57(9):576–82.PubMedGoogle Scholar
  31. 31.
    Kudoh A, Katagai H, Takase H, Takazawa T. Effect of preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anaesthesia. Eur J Anaesthesiol. 2004;21(5):414–6.CrossRefGoogle Scholar
  32. 32.
    Kudoh A. Perioperative management for chronic schizophrenic patients. Anesth Analg. 2005;101(6):1867–72.CrossRefGoogle Scholar
  33. 33.
    Kudoh A, Takase H, Takazawa T. Chronic treatment with antipsychotics enhances intraoperative core hypothermia. Anesth Analg. 2004;98(1):111–5, table of contents.CrossRefGoogle Scholar
  34. 34.
    Patt RB, Proper G, Reddy S. The neuroleptics as adjuvant analgesics. J Pain Symptom Manag. 1994;9(7):446–53.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Yale School of MedicineNew HavenUSA

Personalised recommendations